Value of fine-needle aspiration cytology in diagnosis of Hodgkin's lymphoma and anaplastic large cell lymphoma: one centre experience [Važnost citološke aspiracijske punkcije tankom iglom u dijagnostici Hogkinovog limfoma i anaplastičnog velikostaničnog limfoma: iskustvo jednog kliničkog centra] by Ostojić Kolonić, Slobodanka et al.
Coll. Antropol. 34 (2010) 1: 75–79
Original scientific paper
Value of Fine-Needle Aspiration Cytology in
Diagnosis of Hodgkin’s Lymphoma and Anaplastic
Large Cell Lymphoma: One Centre Experience
Slobodanka Ostoji} Koloni}1,2, Katja Pra{ek-Kudrna2, Vinko Roso2, Delfa Radi}-Kri{to1,
Ana Planinc-Peraica1,2, Sonja D`ebro3, Ika Kardum-Skelin2,4 and Branimir Jak{i}1,2
1 Department of Medicine, University Hospital »Merkur«, Zagreb, Croatia
2 University of Zagreb, School of Medicine, Zagreb, Croatia
3 Department of Pathology and Cytology, University Hospital »Merkur«, Zagreb, Croatia
4 Laboratory for Cytology and Haematology, University Hospital »Merkur«, Zagreb, Croatia
A B S T R A C T
The aim of the study was to determine the value and limitations of cytology in diagnosis of Hodgkin’s lymphoma
(HL) and anaplastic large cell lymphoma (ALCL) as well as differentiation between these two entities. We analysed the
FNA cytodiagnoses and histopathological reports, as well as treatment and survival in 89 newly diagnosed consecutive
patients with these lymphomas treated in our clinical department. These patients (40 male, 49 female; age range 16–93
years; 44 in clinical stages I–II; 38 with B symptoms) were diagnosed and treated during a period of 64 months (1.1.
2004–1.5.2009). The FNA cytodiagnoses were available in 86 patients and the pathohistological diagnoses were avail-
able in 84 patients. Cytology revealed 65 classic HL, 18 ALCL and three patients in which diagnosis was not informative.
Among 65 FNA cytodiagnoses of HL, comparison with histopathology was made in 61 cases and the histopathological
diagnoses were as follows: 56 (91.8%) HL; three ALCL; one diffuse large B cell lymphoma and one marginal zone B cell
lymphoma. In the group of 18 FNA cytodiagnoses of ALCL eight patients (53.3%) had definitive diagnosis of ALCL (ei-
ther as T-cell or O type), five (33.3%) of HL and in three cases a histopathological diagnosis could not be made. These re-
sults confirm the value of FNA in diagnostic procedure in patients with HL and ALCL, especially in HL group of pa-
tients. Since we have an almost uniform group of patients according to therapeutic approach, we did univariate analyses
and found out that patients with FNA cytodiagnoses of HL, younger than 55 years, with early stage of the disease and
without B symptoms had significantly longer overall survival (OS). FNA cytodiagnosis has clinical relevance in differ-
entiation between HL and ALCL.
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Introduction
The role of fine-needle aspiration (FNA) in the diag-
nostic approach to lymphoma has been widely accepted
since 19851. Its success rate usually exceeds 70%, even
approaches 100% in some studies2, but there are still
some controversies about its value in diagnosis and dif-
ferentiation between various subtypes of lymphoma. The
current (2008) WHO (World Health Organization) clas-
sification3, as well the previous (2001) WHO classifi-
cation4, incorporate individual cell morphology, immuno-
phenotype, genetic and clinical parameters when defin-
ing the lymphoma status. Some authors, in their reevalu-
ation of FNA cytodiagnosis of Hodgkin’s lymphoma (HL)
according to the new WHO classification and with the
knowledge that today the therapeutic approach for dif-
ferent subtypes of HL is the same, have concluded that if
the cytology diagnosis of HL is confirmed both by mor-
phology and immunostains, no further tissue biopsy is
necessary5. On the other hand, Jimenez-Heffernan and
co-workers have stated that cytology diagnosis of HL is
not so easy, especially in differentiation between HL and
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anaplastic large cell lymphoma (ALCL) and T-cell- -rich
B-cell lymphoma (TCRBCL)6. It is known that morpho-
logical and immunological similarities do exist between
these entities. Leoncini et al. suggested that HL and
CD30-positive ALCL belong to a continuous spectrum of
malignant disorders7 as well as Schmidt and co-workers
who speculated that TCRBCL represents a phenoty-
pically different manifestation of lymphocyte rich sub-
type of HL8. A similar treatment approach which is ori-
ented to disease biology appears reasonable to our group
and in last five and a half years we have had the same
therapeutic approach for patients with HL and T-cell
ALCL. We were also interested in the estimation of clini-
cal relevance of cytology diagnoses in these lymphoma
groups. To study the value and limitations of cytology,
the cytology diagnoses and histopathological reports, as
well as treatment and survival, were analysed in 89
newly diagnosed consecutive patients with HL and ALCL
treated in our clinical department.
Patients and Methods
During the period of 64 months (1.1.2004–1.5.2009)
89 untreated patients were admitted in our clinical de-
partment with a diagnosis of HL or ALCL. Age of the pa-
tients ranged from 16 to 93 years; the median age was 33
years. Male to female ratio was 40:49. The diagnostic
procedure was done according to the Croatian consensus
of diagnosis and therapy of lymphoma9; clinical stage was
determined according to Ann-Arbor criteria10. 44 pa-
tients were in clinical stages I–II and 38 had B symptoms
at time of diagnosis. Patients were treated with various
chemotherapeutic regimens: ABVD regimen (doxorubi-
cin, bleomycin, vinblastine, dacarbazine), CHOP regi-
men (cyclophosphamide, hydroxydaunomycin, vincristi-
ne and prednisone), LVPP (chlorambucil, vinblastine,
procarbazine and prednisone) and with CHOP-R therapy
(CHOP-rituximab). Response to treatment was assessed
according to the standard criteria9. Overall survival (OS)
was measured from the point of inclusion into the study
until the time of death for any reason, or losing the pa-
tient for the follow up.
The FNA cytodiagnoses were available in 86 patients;
three patients were admitted with histopathological di-
agnoses and without enlarged lymph nodes suitable for
FNA. Cytological samples were analysed on the standard
May-Grünwald-Giemsa stained smears and determina-
tion of cellular markers by smear immunocytochemistry,
applying a panel of CD3, CD15, CD20, CD30, EMA and
ALK (anaplastic lymphoma kinase) monoclonal antibod-
ies.
Histopathology reports and immunohistological re-
sults were available in 84 patients; in one patient with
massive mediastinal lymphadenopathy surgery was not
possible; four patients with enlarged abdominal lymph
nodes refused the surgical procedure. Tissue samples
were fixed in formalin, embedded in paraffin, stained
with haematoxylin and eosin, Giemsa, periodic acid-
-Schiff and Gomori. Immunohistochemical staining was
performed for CD3, CD4, CD15, CD20, CD30, EMA,
ALK, PAX5, EBV-LMP and MUM1.
The FNA cytodiagnoses of HL and ALCL were com-
pared with the corresponding histopathology reports.
The univariate analyses were used on statistical data
processing, and Kaplan-Meier method for the analysis of
survival (Statistica 7.1, StatSoft Inc.,Tulsa, USA).
Results
Overall, FNA cytodiagnoses included 65 classical HL,
18 ALCL and three cases in which diagnosis was not infor-
mative due to inadequate material. Among the 65 FNA
cytodiagnoses of HL comparison with histopathology was
done in 61 cases (in three cases a biopsy of lymph node
was not possible and in one case there was no tumour in-
filtration in the analyzed lymph node). The histopatho-
logical diagnoses were as follows: 56 (91.8%) HL; three
ALCL; one diffuse large B-cell lymphoma and one mar-
ginal zone B cell lymphoma (Table 1). FNA cytodiagnosis
of mixed cellularity (HL-MC) was made in 31 (55.4%)
cases; in 21 (67.7%) cases the FNA cytodiagnosis of HL-
-MC was in agreement with the histopathology report,
while in 10 cases the histological diagnosis was nodular
sclerosis. In the group of 18 FNA cytodiagnoses of ALCL
two patients did not have a lymph node biopsy; in one case
no tumour was found in the biopsy; eight patients (53.3%)
had definitive diagnosis of ALCL (either T-cell or 0 type),
five (33.3%) as HL and two as T-cell non-Hodgkin’s lym-
phoma (Table 1). These results confirm the value of FNA
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TABLE 1
CORRELATION OF FNA CYTODIAGNOSES WITH
HISTOPATHOLOGICAL DIAGNOSES
FNA
cytodiagnosis
Number
of cases
Histopathological diagnosis
HL ALCL Other + (*)
HL-MC 34 31 1 (2)
HL-NS 13 12 1 –
HL-NS II 5 3 – 1 + (1)
HL-MC/NS II 1 1 – –
HL-LR 7 4 1 1 + (1)
HL NOS 5 5 – –
ALCL 0 11 3 6 (2)
ALCL T 4 – 2 1 + (1)
ALCL 3 2 – 1
Total HL 65 56 3 2 + (4)
Total ALCL 18 5 8 2 + (3)
HL/ALCL 3 2 1 –
Total 86 63 12 4 + (7)
HL – MC – Hodgkin’s lymphoma – mixed cellularity, HL – NS –
Hodgkin’s lymphoma – nodular sclerosis, HL – LR – Hodgkin’s
lymphoma – lymphocyte rich, HL NOS – Hodgkin’s lymphoma,
not otherwise specified, ALCL – anaplastic large cell lymphoma
* histopathological diagnosis was not available and/or there was
no tumour infiltration
in diagnostic approach for patients with HL and ALCL,
especially in HL group of patients.
According to the standard therapeutic approach in
our clinical department, all patients with diagnosis of HL
and T-cell ALCL are treated with the same regimen-
ABVD. LVPP regimen is reserved for older patients with
serious comorbidity. 86 of our patients were treated with
chemotherapy: 74 received ABVD, four received LVPP,
seven received CHOP and one patient received CHOP- R;
two patients refused therapy because of age (one patient
was 79 and the other one was 93 years old) and one pa-
tient died during the diagnostic procedure.
The overall survival was 89%. Since we had an almost
uniform group of patients according to therapeutic ap-
proach (the majority of patients received ABVD), we did
univariate analyses and found out that some tested pa-
rameters (age, clinical stage, presence of B symptoms
and FNA cytodiagnosis) proved to be clinically signifi-
cant. Patients with a FNA cytodiagnosis of HL had a
better prognosis (p=0.003, Figure 1). Patients who were
diagnosed in the early stage of the disease (p=0.047) as
well as patients without B symptoms (p=0.037) had sig-
nificantly longer overall survival as is shown in Figures 2
and 3, respectively. Also, according to our results (Figure
4) patients younger than 55 years at time of diagnosis
also had a better prognosis (p=0.037).
Discussion and Conclusion
FNA cytology offers a rapid, first-level diagnostic ap-
proach for patients with lymphadenopathies. Many au-
thors emphasize the reliability of this method in making
an accurate initial recognition of lymphomas, especially
that of Hodgkin’s lymphoma2,5,11. Jimenez-Heffernan
and co-workers, in a review of 170 cytodiagnoses of HL
evaluated the diagnostic accuracy and pitfalls of FNA in
the initial evaluation of this lymphoma by comparing the
results during two periods (first period 1982–1990; sec-
ond period 1991–1999)6. They found that 15 cytology di-
agnoses of HL were followed by different histology diag-
noses and that the sensitivity of the method varied from
79.3% in the first period to 84.9% in the second. Diagnos-
tic errors with major consequences for patient manage-
ment diminished from 14 in the first period to five in the
second, probably because of wider implement of immu-
nostaining. Zhang and Raza, in their analysis of 42 pa-
tients with FNA cytodiagnoses of HL, found 100% agree-
ment with the pathohistologic results and even proposed
S. Ostoji} Koloni} et al.: Value of Cytology in Diagnosis of Lymphoma, Coll. Antropol. 34 (2010) 1: 75–79
77
Fig. 1. Cumulative survival according to FNA cytodiagnosis. HL
– Hodgkin’s lymphoma, ALCL – Anaplastic large cell lym-
phoma, p=0.00328 (p<0.01).
Fig. 2. Cumulative survival according to disease stage. I–II –
early stage disease, III–IV – late stage disease, p=0.0467 (p<0.5).
Fig. 3. Cumulative survival according to presence of B symp-
toms, p=0.03697 (p<0.05).
Fig. 4. Cumulative survival according to age at time of diagno-
sis, p=0.0368 (p<0.05).
that FNA cytodiagnosis of HL, confirmed both by mor-
phology and immunostaining, is enough for the diagno-
sis5. Our results (91.8% in agreement with the histolo-
gical diagnosis in 61 analysed cases) confirm the value of
FNA in diagnostic approach for patients with HL. The
cytologists are aware that FNA cytodiagnosis of HL can
be more difficult in some cases: lymphocyte-depleted
HL12, hypocellular and nondiagnostic aspirates of nodu-
lar sclerosis, presence of Reed-Sternberg (R-S) cells and
R-S like cells in other lymphoma subtypes and nonlym-
phomatous lesions, paucity of diagnostic R-S cells in
FNA smears13. In our study analysis of HL subtypes
showed that the highest agreement with histopathology
reports was in the group of patients with mixed cellu-
larity (67.7%). Interestingly, during this period of almost
five and a half years there were no FNA cytodiagnoses of
lymphocyte-depleted HL. FNA cytodiagnosis of nodular
sclerosis was made in 18 cases (13 as NS and five as NSII
subtype) and in seven (41.2%) patients the histopatho-
logy report confirmed that subtype. In their study of
Jogai et al. proposed presence of numerous lacunar- type
cells along with fibroblasts and colagenous material as
useful pointers toward diagnosis of nodular sclerosis
variant14.
In two cases of HL (nodular sclerosis type II and lym-
phocyte rich variant) the histopathology report was B
cell lymphoma (one diffuse large cell and one marginal
zone lymphoma) and that lead to the change of therapeu-
tic plan. These patients received CHOP and CHOP-R
therapy.
The FNA cytodiagnosis of ALCL can be a difficult
task, but the results of Rapkiewicz and co-workers have
showed that this lymphoma entity can be accurately di-
agnosed by this method15. They stressed the importance
of obtaining adequate material, keeping a wide differen-
tial diagnostic procedure and utilization both immu-
nochemistry and molecular techniques. The morphologic
clue is a careful evaluation of hallmark cells and wreath-
-like multinucleated giant cells, including the necessary
staining for ALK. In our study 18 FNA cytodiagnoses of
ALCL were made and comparison with the pathohistolo-
gical reports was possible in 15 patients. Eight patients
(53.3%) had definitive diagnosis of ALCL (either T-cell or
0 type), five (33.3%) as HL and two as T-cell non-Hodg-
kin’s lymphoma. These results are expected because we
are all aware of morphological and clinical overlapping
between HL, ALCL and T-cell lymphoma16. Some au-
thors have suggested that proper interpretation of cyto-
logical features together with judicious use of immuno-
cytochemical results can help in reducing errors in diag-
nosing these subtypes1.
HL and ALCL have a similar biological pathway and
in our clinical department the same therapeutic ap-
proach is established for patients with classic HL and
T-cell ALCL: ABVD. LVPP regimen is reserved for older
patients with serious comorbidity. 86 of our patients
were treated with chemotherapy and 78 (90.6%) received
either ABVD (74) or LVPP (four). Two patients refused
therapy because of age (one patient was 79 and the other
one was 93 years old) and one patient died during the di-
agnostic procedure. The overall survival was high, 89%,
as we expected. Since we have an almost uniform group
of patients according to therapeutic approach we did
univariate analyses to find out which of the tested pa-
rameters (age, clinical stage, presence of B symptoms
and FNA cytodiagnosis) could be clinically significant.
The patients younger than 55 years, who were diagnosed
in the early stage of the disease as well as patients with-
out B symptoms had significantly longer overall survival.
Also, patients with an FNA cytodiagnosis of HL had a
better prognosis.
These results confirm the value and accuracy of FNA
cytology in initial diagnostic approach for patients with
HL and ALCL, as well as its clinical relevance in the dif-
ferentiation between these lymphoma entities.
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VA@NOST CITOLO[KE ASPIRACIJSKE PUNKCIJE TANKOM IGLOM U DIJAGNOSTICI
HOGKINOVOG LIMFOMA I ANAPLASTI^NOG VELIKOSTANI^NOG LIMFOMA: ISKUSTVO
JEDNOG KLINI^KOG CENTRA
S A @ E T A K
Cilj studije bio je procijeniti vrijednost i ograni~enja citologije u dijagnostici i razlikovanju Hodgkinovog limfoma
(HL) i anaplasti~nog velikostani~nog limfoma (ALCL). Analizirali smo po~etne citolo{ke dijagnoze, rezultate patohisto-
lo{ke obrade, u~inke terapije i pre`ivljenje u 89 novodijagnosticiranih bolesnika s tim limfomima koji su lije~eni na
na{em klini~kom odjelu. U 89 bolesnika (40 mu{karaca, 49 `ena; u dobi od 16 do 93 godine; 44 u klini~kom stadiju I–II,
38 s B simptomima) bila je postavljena dijagnoza i lije~eni su u vremenskom razdoblju od 64 mjeseca (1.1.2004.–1.5.
2009. god.). Citolo{ka dijagnostika bila je mogu}a u 86 bolesnika, a patohistolo{ku dijagnozu bilo je mogu}e postaviti
kod 84 bolesnika. Citolo{ka aspiracijska punkcija otkrila je 65 klasi~nih HL-a, 18 ALCL-a, a u 3 bolesnika dijagnoza nije
bila informativna. U skupini 65 citolo{kih dijagnoza HL-a, usporedba s patohistologijom je napravljena u 61 slu~aju, a
pripadaju}e patohistolo{ke dijagnoze bile su: 56 (91,8%) HL-a, tri ALCL-a, jedan difuzni velikostani~ni B limfom i jedan
B- stani~ni limfom marginalne zone. U grupi od 18 citoto{kih dijagnoza ALCL-a, patohistolo{ke dijagnoze bile su slje-
de}e: osam bolesnika (53,3%) imalo je definitivnu dijagnozu ALCL-a (bilo T-stani~ni ili 0-tip), pet bolesnika (33,3%)
imalo je dijagnozu HL-a, dok u tri slu~aja nije bilo mogu}e postaviti patohistolo{ku dijagnozu. Ti rezultati potvr|uju
vrijednost citolo{ke dijagnostike u dijagnosti~kom postupku kod bolesnika sa HL-om i ALCL-om, naro~ito kod boles-
nika sa HL-om. S obzirom da imamo gotovo jednoliku skupinu bolesnika s obzirom na primijenjenu terapiju, napravili
smo univarijatne analize koje su pokazale da pacijenti s citolo{kom dijagnozom HL-a, mla|i od 55 godina, u ranom
stadiju bolesti i bez B simptoma imaju znatno du`e ukupno pre`ivljenje. Citolo{ka dijagnostika ima klini~ku va`nost u
razlikovanju HL-a i ALCL-a.
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